



Continuing Education, Inc
UNIVERSITY AT SEA™

Presents

**Topics in Gastroenterology and Hepatology: 2023
Update**

14 AMA PRA Category 1 Credits™

14 ACPE Credits

Up to 14 (part II) MOC points in medical knowledge in the American Board of Internal
Medicine's (ABIM) Maintenance of Certification (MOC) program

14.0 Contact Hours

2 Hours of Pharmacology for Nurse Practitioners

Lisbon, Portugal

Celebrity Infinity

April 26 - May 06, 2023

With

Keyur Patel, MD, PhD

and

Martin H. Poleski, MD, CM, FACP, AGAF

CONTINUING EDUCATION, INC.
Topics in Gastroenterology and Hepatology: 2023 Update
 April 26 - May 06, 2023

Agenda

April 26, 2023	Meet and Greet – 6:30pm – 7:30pm Cellar Masters, 4th Floor	
April 27, 2023	No Events Today	
April 28, 2023	5:30pm – 6:30pm	Networking and Case Discussions – Cellar Masters, 4 th Floor
April 29, 2023 Educational Sessions Conference Center 3rd Floor	Time	Topic
	8:30am – 9:30am	<i>Evaluation of Abnormal Liver Tests - Dr. Patel</i>
	9:30am – 10:30am	<i>Irritable Bowel Syndrome IBS-C and Pain - Dr. Poleski</i>
	10:30am – 11:30am	<i>Hepatitis C Screening Management - Dr. Patel</i>
	11:30am – 12:30pm	<i>Chronic & Recurring Diarrhea - Dr. Poleski</i>
	12:30pm – 1:30pm	Lunch on your own
	1:30pm – 2:30pm	<i>Diagnosis and Management of Chronic Hepatitis B - Dr. Patel</i>
	2:30pm – 3:30pm	<i>Screening for Colon and Rectal Cancer - Dr. Poleski</i>
3:30pm – 4:30pm	<i>Diagnosis and Management of NAFLD - Dr. Patel</i>	
April 30, 2023	No Events Today	
May 1, 2023	5:30pm – 6:30pm	Networking and Case Discussions – Cellar Masters, 4 th Floor
May 2, 2023	No Events Today	
May 3, 2023 Educational Sessions Conference Center 3rd Floor	Time	Topic
	8:30am – 9:30am	<i>Inflammatory Bowel Disease: Ulcerative Colitis - Dr. Poleski</i>
	9:30am – 10:30am	<i>Management of End-Stage Liver Disease - Dr. Patel</i>
	10:30am – 11:30am	<i>Inflammatory Bowel Disease: Chron’s Disease – Dr. Poleski</i>
	11:30am – 12:30pm	<i>Drug-Induced Liver Injury - Dr. Patel</i>
	12:30pm – 1:30pm	Lunch on your own
	1:30pm – 2:30pm	<i>Peptic Ulcer Disease - Dr. Poleski</i>
	2:30pm – 3:30pm	<i>Alcohol Related Liver Disease - Dr. Patel</i>
3:30pm – 4:30pm	<i>Inflammatory Esophageal Diseases - Dr. Poleski</i>	
May 4, 2023	6:30pm – 7:30pm	Networking and Case Discussions – Cellar Masters, 4 th Floor
May 5, 2023	5:30pm – 6:30pm	Networking and Case Discussions – Cellar Masters, 4 th Floor
May 6, 2023	Have a Safe Trip Home	

CONTINUING EDUCATION, INC.
Topics in Gastroenterology and Hepatology: 2023 Update
April 26 - May 06, 2023

Faculty

Keyur Patel, MD, PhD
Associate Professor of Medicine
University of Toronto, Division of Gastroenterology
UHN Toronto, ON, Canada

Dr. Patel received his Medical degree from the University of Southampton, United Kingdom and completed his clinical fellowships in Internal Medicine and Gastroenterology/Hepatology in Western Australia. He received his PhD from University of Sydney.

He completed a 3-year post-doctoral research fellowship in Clinical and Translational Research in viral hepatitis at Scripps Clinic and Research Foundation, San Diego, CA and Duke Clinical Research Institute, Durham NC. He was on faculty at Duke University 2004-2015, and is now at University of Toronto since 2016. His research interests include early phase clinical therapeutic trials for viral hepatitis and NASH fibrosis, and the development non-invasive biomarkers of fibrogenesis.

Martin H. Poleski, MD,CM, FACP, AGAF
Professor of Medicine, Duke University
Duke Regional Hospital, Durham, North Carolina

Dr. Poleski is currently Professor of Medicine at Duke University in the Department of Medicine, Division of Gastroenterology, Duke University. He was Chief of Gastroenterology at Duke Regional Hospital (DRH) and Director of the Endoscopy from 2008 to 2016.

Dr. Poleski created the modern DRH Gastroenterology Department, starting with one Gastroenterologist in 2008, and now includes 8 Gastroenterologist. He is currently a full time Professor of Medicine at Duke University with a full time practice at Duke University clinics and endoscopy centers.

Dr. Poleski graduated McGill University, Montreal, in 1973 with an MD. He did his Internal medicine training at The University of Toronto and McGill University. In academic year 1975-76 he was Chief Medical Resident at The Jewish General Hospital of McGill University. He did a fellowship in Gastroenterology at Memorial Sloan Kettering , part of the Cornell Hospitals in New York City.

After completing his fellowship he returned to the Jewish General hospital as a consultant in Gastroenterology, developed the first Inflammatory Bowel Disease center at that hospital and at McGill University. He eventually rose in the ranks to become an Assistant Professor of Medicine at McGill University.

He joined the Scripps Clinic Medical Group in La Jolla , California at the end of 1992 as a consultant in Gastroenterology. He subsequently became Director of the Inflammatory Bowel Disease Center and Director of the Fellowship program in Gastroenterology and Hepatology at Scripps clinic.

He also had an appointment at UCSD as Clinical Professor of Medicine. In the summer of 2003 he joined the faculty of Duke University as Professor of Medicine and senior consultant in Gastroenterology. He has continued his interest in inflammatory Bowel disease (IBD), involved in clinical studies and having a clinic at Duke University Medical Center dedicated to IBD.

CONTINUING EDUCATION, INC.
Topics in Gastroenterology and Hepatology: 2023 Update
April 26 - May 06, 2023

Accreditation

Joint Accreditation

In support of improving patient care, Continuing Education, Inc./University at Sea™ is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

Designation: Continuing Education, Inc. designates this live activity for a maximum of 14 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

Designation: Continuing Education, Inc. designates this live activity for a maximum of 14 ACPE Credits.

Nurses

Designation: Nurses completing this educational activity will receive a maximum of 14 contact hours.

This activity provides 2 hours of pharmacology for nurse practitioners

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16 (part II) MOC points in medical knowledge in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disabilities among participants

Continuing Education, Inc., and Celebrity Cruises do not discriminate against persons on the basis of disability and seek to accommodate, to the extent possible, the special needs of persons with disabilities. Travelers need to be aware, however, that certain land and shore facilities may not be fully accessible to disabled persons. Special medical, physical or other requirements must be identified at the time of booking. The CEI Activity Coordinator accompanying this program will provide assistance for participants and liaison with the ship's company.

CONTINUING EDUCATION, INC.
Topics in Gastroenterology and Hepatology: 2023 Update
April 26 - May 06, 2023

Disclosures

Continuing Education, Inc., seeks to ensure balance, independence, objectivity and scientific rigor in all of its sponsored educational activities. CEI has no relationships with the manufacturers of products or devices discussed in these presentations. None of the planners of this educational activity has any relevant financial relationships to disclose.

Speakers participating in CME programs are asked to disclose any involvement with commercial organizations and their responses are indicated below. In addition, any unlabeled or investigational uses of pharmaceuticals or equipment must be identified to participants during presentations. The existence of commercial relationships does not prevent speakers from making presentations. The intent of this CEI policy is consistent with requirements of the Accreditation Council for CME and is designed to provide complete information to the audiences. Participants must make their own judgments about the content of presentations in light of these disclosures and determine if possible bias or misrepresentation has occurred.

Faculty members further affirm (1) that all recommendations involving clinical medicine given during presentations are based upon evidence that is accepted within the profession of medicine for the care of patients, (2) that any scientific research referred to in support or justification for a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis, and (3) that they will not present recommendations, treatments or manners of practicing medicine that are not within the definition of CME, or are known to have risks or dangers that outweigh the benefits, or are known to be ineffective in the treatment of patients.

Keyur Patel, MD, PhD

Dr. Patel has reported no relationships with ineligible companies and has agreed to identify any off-label or investigational uses of pharmaceuticals or equipment referenced during all presentations.

Martin H. Poleski, MD,CM, FACP, AGAF

Dr. Poleski has reported no relationships with ineligible companies and has agreed to identify any off-label or investigational uses of pharmaceuticals or equipment referenced during all presentations.

CONTINUING EDUCATION, INC.
Topics in Gastroenterology and Hepatology: 2023 Update
April 26 - May 06, 2023

Topics and Objectives

- **Evaluation of Abnormal Liver Tests**
 - Differentiate between tests of liver function and liver injury
 - Use a diagnostic algorithm in the work-up of abnormal liver tests
- **Diagnosis and Management of Chronic Hepatitis B**
 - Describe HBV serology for diagnosis and management
 - Recognize at risk populations for vaccination
 - Apply practice guidelines for management and treatment of hepatitis B infection
- **Hepatitis C screening and management**
 - Understand screening recommendations for HCV
 - Use optimal treatment regimens for chronic hepatitis C patients
 - Diagnosis and management of Non-alcoholic fatty liver disease
- **Recognize NAFLD as an important metabolic disease**
 - Understand the natural history of NAFLD
 - Use basic diagnostic approaches for identify patients at risk with risk for advanced disease
 - Employ current approaches for management of NAFLD
- **Management considerations in end-stage liver disease**
 - Describe common complications associated with cirrhosis
 - Understand management options in patients with end-stage liver disease
 - Use effective screening and surveillance methods to detect complications of cirrhosis
- **Drug-induced liver Injury**
 - Differentiate types of liver injury
 - Describe common drugs and herbals implicated in liver injury
 - Understand management approaches to patients with drug-induced liver injury
- **Alcohol-related liver disease**
 - Recognize alcohol use disorder
 - Determine prognosis in alcoholic hepatitis
 - Understand management options for alcoholic hepatitis
- **Screening for Colon and rectal cancer**
 - Improve the outcome and cost effectiveness of screening for Colon Cancer with new guidelines and new screening tests
- **Irritable Bowel Syndrome (IBS)**
 - Improve cost effectiveness of management of IBS
 - Explain current management of IBS, Constipation and Chronic abdominal pain and how they differ. and the place of new medications
- **Inflammatory Bowel Disease**
 - Share on going changes in treatment of Crohn's disease and Ulcerative colitis.
- **Inflammatory Esophageal Diseases**
 - Discuss new etiologies of chest pain, heartburn and dysphagia
 - Discuss the relationship of Barrett's Esophagus to Chronic reflux Esophageal cancer in perspective
- **Peptic Ulcer disease**
 - Explain new recommendations in the prevention and treatment of Peptic Ulcer disease and its complications
- **Chronic and recurring diarrhea**
 - Illustrate the place of the primary care physicians in the diagnosis and management of chronic diarrhea